Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

JAK inhibitors show promise for treating various skin diseases.

Certain surgical methods are better than routine incision for hidradenitis suppurativa, topical clindamycin and acitretin are effective treatments, men with HS have a risk of skin cancer, HS patients are more likely to die from heart problems, and specific genetic markers are linked to treatment response.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Using anabolic androgenic steroids can cause serious, lasting health problems in many parts of the body.

Some skin conditions may increase the risk of heart disease, but are not yet included in cardiovascular prevention guidelines.

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Severe hair loss links to metabolic issues in older men with psoriasis.

Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Baricitinib is effective and safe for treating severe alopecia areata.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

Some men with early hair loss may have a male version of PCOS, affecting hormones and increasing health risks.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Some skin conditions may increase the risk of heart disease, and understanding their connection could lead to better treatments.

Skin diseases like psoriasis, lupus, and others can increase heart disease risk due to factors like chronic inflammation and genetic susceptibility.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

The document concludes that future heart disease research should account for sex-specific differences to improve diagnosis, treatment, and outcomes.

Obesity is an independent risk factor for early coronary artery disease (CAD) and its severity is not affected by age.

Finasteride for hair loss can cause erectile dysfunction due to tissue fibrosis.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Finasteride for hair loss may cause lasting sexual, genitourinary, mental, and anti-androgenic side effects in young men.

Lower LDL-c levels predict higher COVID-19 mortality.

Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.